• LAST PRICE
    1.1400
  • TODAY'S CHANGE (%)
    Trending Up0.0300 (2.7027%)
  • Bid / Lots
    1.0900/ 6
  • Ask / Lots
    1.1500/ 51
  • Open / Previous Close
    1.1200 / 1.1100
  • Day Range
    Low 1.0900
    High 1.1400
  • 52 Week Range
    Low 0.6839
    High 2.1200
  • Volume
    333,250
    below average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table. Wednesday's close: 1.11
TimeVolumeOTLK
09:32 ET6261.1
09:33 ET1001.1254
09:35 ET6001.115
09:37 ET5001.12
09:39 ET3891.1114
09:42 ET3001.105
09:44 ET2301.105
09:51 ET6001.11
09:53 ET20001.11
09:55 ET2001.11
09:57 ET35391.1
10:00 ET7001.1
10:04 ET12001.1
10:06 ET3001.1
10:08 ET13001.1
10:11 ET20001.1
10:15 ET37431.1
10:20 ET4001.1
10:22 ET192881.1
10:24 ET7501.1
10:26 ET25001.1
10:27 ET4001.11
10:29 ET5831.1
10:31 ET2001.1
10:33 ET6001.1
10:36 ET1001.1
10:38 ET8001.1
10:40 ET47781.1
10:42 ET19521.095
10:44 ET58001.1
10:45 ET4001.1
10:49 ET2151.1
10:51 ET3001.1
10:54 ET2001.11
10:56 ET2001.11
10:58 ET2001.11
11:00 ET2151.1
11:02 ET6001.11
11:03 ET3001.105
11:05 ET4001.105
11:07 ET2001.1
11:09 ET3001.1
11:12 ET2001.1
11:14 ET4001.11
11:16 ET6001.1
11:18 ET2001.105
11:20 ET4001.11
11:21 ET5001.1
11:23 ET4001.1
11:25 ET5001.11
11:27 ET1001.1
11:30 ET5221.105
11:32 ET5001.11
11:34 ET3001.105
11:36 ET2491.1
11:38 ET1001.1
11:41 ET1001.1
11:43 ET1001.105
11:45 ET1001.105
11:48 ET1001.1
11:50 ET1001.1
11:52 ET1001.1
11:56 ET1001.1
12:03 ET3871.1
12:06 ET4001.1017
12:08 ET2001.1
12:10 ET3001.1
12:12 ET1001.1
12:15 ET1001.1
12:19 ET6451.1074
12:21 ET7001.105
12:24 ET2501.1001
12:28 ET1001.1
12:30 ET8221.1
12:33 ET1001.1
12:37 ET1001.1
12:39 ET26321.1
12:44 ET175641.11
12:46 ET3001.11
12:48 ET1001.11
12:51 ET1001.11
12:53 ET1001.11
12:55 ET2001.11
12:57 ET2001.11
01:00 ET4661.11
01:02 ET1001.11
01:06 ET3001.115
01:08 ET2001.11
01:09 ET1001.111
01:11 ET15001.11
01:13 ET1001.11
01:15 ET9001.115
01:20 ET1001.11
01:22 ET1001.11
01:24 ET10001.115
01:26 ET26001.11
01:27 ET1001.11
01:29 ET18881.11
01:31 ET2001.11
01:36 ET5001.11
01:38 ET2001.11
01:40 ET1001.11
01:44 ET1001.11
01:47 ET10001.1128
01:49 ET2001.11
01:51 ET19181.11
01:56 ET3001.11
02:00 ET42001.11
02:02 ET1001.1
02:03 ET2001.1
02:05 ET3001.105
02:07 ET181211.11
02:14 ET15541.11
02:16 ET2001.1134
02:21 ET13001.11
02:23 ET1001.1104
02:25 ET8221.11
02:27 ET2001.11
02:30 ET1001.11
02:32 ET1001.11
02:34 ET14771.11
02:36 ET54001.115
02:38 ET28001.12
02:39 ET8001.12
02:45 ET2001.12
02:52 ET3001.12
02:54 ET124471.12
02:56 ET6001.12
02:59 ET21001.12
03:01 ET22001.12
03:03 ET16001.12
03:06 ET2001.12
03:10 ET11001.12
03:12 ET11501.1121
03:14 ET18651.12
03:15 ET7001.12
03:17 ET24811.1199
03:19 ET15961.12
03:21 ET55001.11
03:24 ET48001.12
03:26 ET8971.12
03:28 ET11111.12
03:32 ET13001.12
03:33 ET30491.12
03:35 ET2001.125
03:37 ET69851.12
03:39 ET117741.115
03:42 ET22811.12
03:44 ET34001.12
03:46 ET70831.12
03:48 ET18001.12
03:50 ET8001.115
03:51 ET67351.125
03:53 ET85981.12
03:55 ET8001.12
03:57 ET32001.12
04:00 ET664211.14
Data delayed at least 15 minutes.
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesOTLK
Outlook Therapeutics Inc
284.9M
-3.7x
---
United StatesRLYB
Rallybio Corp
285.6M
-3.7x
---
United StatesLIAN
LianBio
287.1M
-2.4x
---
United StatesATNM
Actinium Pharmaceuticals Inc
284.6M
-8.8x
---
United StatesPDSB
PDS Biotechnology Corp
277.9M
-9.2x
---
United StatesSVRA
Savara Inc
292.0M
-10.0x
---
As of 2023-01-26

Company Information

Outlook Therapeutics, Inc. (Outlook) is a clinical-stage biopharmaceutical company. The Company focuses on developing and commercializing ONS-5010 (LYTENAVA (bevacizumab-vikg)), an ophthalmic formulation of bevacizumab for use in retinal indications. ONS-5010, is the Company's product candidate, which is developed to be administered as an intravitreal injection for the treatment of wet age-related macular degeneration (wet AMD) and other retinal diseases. Bevacizumab is a full-length, humanized anti-VEGF (Vascular Endothelial Growth Factor) recombinant monoclonal antibody (mAb), that inhibits VEGF and associated angiogenic activity. Its clinical program for ONS-5010 in wet AMD involves three clinical trials, which includes NORSE ONE, NORSE TWO and NORSE THREE. Outlook sells ONS-5010 in the United States, United Kingdom, Europe, Japan and other markets for the treatment of wet AMD, diabetic macular edema (DME), and branch retinal vein occlusion (BRVO).

Contact Information

Headquarters
485 Route 1 South, Building F, Suite 320ISELIN, NJ, United States 08830
Phone
609-619-3990
Fax
---

Executives

Director
Ralph Thurman
President, Chief Executive Officer, Director
C. Russell Trenary
Chief Financial Officer, Executive Vice President, Treasurer, Company Secretary, Director
Lawrence Kenyon
Chief Operations Officer
Terry Dagnon
Senior Vice President - Marketing & Market Access
Alicia Tozier

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
$284.9M
Revenue (TTM)
$0.00
Shares Outstanding
256.7M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
0.67
EPS
$-0.31
Book Value
$0.04
P/E Ratio
-3.7x
Price/Sales (TTM)
---
Price/Cash Flow (TTM)
---
Operating Margin
---
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.